FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
Plastic surgeon Johnny Franco, MD, discusses how his firsthand experience with GLP-1s shaped his patient-centered wellness program and what plastic surgeons should know before adding similar treatments to their aesthetic practices.